Related Experiment Video
Updated: Feb 10, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Immunopeptidomic Profiling of HLA-A2-Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target
Nicola Ternette1,2, Marloes J M Olde Nordkamp3, Julius Müller1
1The Jenner Institute, University of Oxford, Oxford, OX3 7FZ, UK.
Abstract:
The recent development in immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cells in the treatment of cancer has not only demonstrated the potency of utilizing T-cell reactivity for cancer therapy, but has also highlighted the need for developing new approaches to discover targets suitable for such novel therapeutics. Here we analyzed the immunopeptidomes of six HLA-A2-positive triple negative breast cancer (TNBC) samples by nano-ultra performance liquid chromatography tandem mass spectrometry (nUPLC-MS2 ). Immunopeptidomic profiling identified a total of 19 675 peptides from tumor and adjacent normal tissue and 130 of the peptides were found to have higher abundance in tumor than in normal tissues. To determine potential therapeutic target proteins, we calculated the average tumor-associated cohort coverage (aTaCC) that represents the percentage coverage of each protein in this cohort by peptides that had higher tumoral abundance. Cofilin-1 (CFL-1), interleukin-32 (IL-32), proliferating cell nuclear antigen (PCNA), syntenin-1 (SDCBP), and ribophorin-2 (RPN-2) were found to have the highest aTaCC scores. We propose that these antigens could be evaluated further for their potential as targets in breast cancer immunotherapy and the small cohort immunopeptidomics analysis technique could be used in a wide spectrum of target discovery. Data are available via ProteomeXchange with identifier PXD009738.
Insights
New immunotherapies like CAR T-cells need novel targets. This study identified five potential breast cancer targets, Cofilin-1, IL-32, PCNA, syntenin-1, and ribophorin-2, using immunopeptidomics.
Area of Science:
- Oncology
- Immunology
- Proteomics
Background:
- Advances in cancer immunotherapy, including immune checkpoint inhibitors and CAR T-cells, highlight the need for novel therapeutic targets.
- Identifying specific tumor antigens is crucial for developing effective T-cell-based cancer therapies.
Purpose of the Study:
- To discover potential therapeutic targets for breast cancer immunotherapy by analyzing tumor immunopeptidomes.
- To evaluate the utility of small cohort immunopeptidomics for antigen discovery.
Main Methods:
- Analysis of immunopeptidomes from six HLA-A2-positive triple-negative breast cancer (TNBC) samples using nano-ultra performance liquid chromatography tandem mass spectrometry (nUPLC-MS²).
- Quantification of peptide abundance in tumor versus adjacent normal tissues.
- Calculation of average tumor-associated cohort coverage (aTaCC) to identify highly abundant tumor-specific peptides.
Main Results:
- A total of 19,675 peptides were identified, with 130 peptides showing higher abundance in tumor tissues.
- Cofilin-1 (CFL-1), interleukin-32 (IL-32), proliferating cell nuclear antigen (PCNA), syntenin-1 (SDCBP), and ribophorin-2 (RPN-2) exhibited the highest aTaCC scores.
- These proteins represent promising candidates for breast cancer immunotherapy targets.
Conclusions:
- The identified proteins (CFL-1, IL-32, PCNA, SDCBP, RPN-2) warrant further investigation as potential targets for breast cancer immunotherapy.
- Small cohort immunopeptidomics is a viable technique for discovering novel cancer antigens.
- The study provides a valuable dataset (ProteomeXchange identifier PXD009738) for future research.
Related Concept Videos
Positive, Negative, and Zero Work
Positive and Negative Feedback Loops
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Design Example: Identifying the Locations of Monuments in the Field Using Global Positioning System Device
Scalar and Vector Triple Products
The scalar triple product is the dot product of a vector with the cross product of two vectors....

